Coya Therapeutics Publishes Study Linking Biomarkers to ALS Progression and Survival
Coya Therapeutics, a clinical-stage biotechnology company, has announced the publication of a study that demonstrates significant correlations between certain biomarkers and the progression and survival rates of patients with Amyotrophic Lateral Sclerosis (ALS). The research, led by Dr. David Beers and Dr. Stanley Appel at the Houston Methodist Neurological Institute, was published in the Annals of Clinical and Translational Neurology. The study involved 100 ALS patients and 100 healthy controls, focusing on biomarkers such as 4-hydroxy-2-nonenal (4-HNE), lipopolysaccharide binding protein (LBP), and neurofilament light chain (NfL). These biomarkers were found to be elevated in ALS patients and correlated with disease progression and survival. The study supports the mechanistic rationale for COYA 302, an investigational product by Coya Therapeutics, which is currently being evaluated in the ALSTARS Trial, a Phase 2 study. 
